Crizotinib in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma in the setting of renal insufficiency: a case report

Table 1 Reported cases of the use of crizotinib in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma

Study	Age	Stage (Ann Arbor)	ECOG	Previous therapy lines	Response, in months
Gambacorti Passerini et al. 2014 [11]	26	IIIB	2	CHOP, DHAP, HD-VP16	CR, >40
	19	IVB	3	CHOP, DHAP, BEAM	CR, 2
	22	IIB	1	CHOP, VAD, H-CyVAD	CR, >35
	20	IIB	2	CHOP, DHAP, BEAM	CR, 2
	47	IIIB	2	IEV, CHOP, DHAP	CR, >30
	28	IIIBe	2	CHOP, DHAP, miniBEAM	CR, 2
	34	IVBe	2	CHOP, ESHAP	CR, 3
	38	IVB	4	CHOP, DHAP, VIM	CR, 8
	55	IIIB	1	CHOP	CR, >21
Ordemann et al. 2013 [12]	29	na	na	CHOP-21, DHAP, Dexa-BEAM	PR, 1
Cleary et al. 2014 [13]	34	na	na	CHOP, gemcitabine-based therapy, pralatrexate, Mtx, brentuximab	CR, 30; allo-SCT at week 13
Conyers et al. 2014 [14]	22	IIIB	na	CHOP	CR, >21; allo-SCT at 2 months
Current case	48	IV	3	CHOP, ICE	CR, >29

allo-SCT allogeneic stem cell transplant, BEAM carmustine, etoposide, cytarabine, melphalan, CHOP cyclophosphamide, doxorubicin (adriamycin), vincristine, prednisone, CR complete response, Dexa-BEAM dexamethasone, carmustine, etoposide, cytarabine, melphalan, DHAP dexamethasone, cisplatin, cytarabine, ECOG Eastern Cooperative Group, ESHAP etoposide, methylprednisolone, cytarabine, cisplatin, H-CyVAD alternate regimens of 1) cyclophosphamide, vincristine, doxorubicin (adriamycin), dexamethasone; 2) methotrexate and cytarabine; HD-VP16 high-dose etoposide, ICE ifosfamide, carboplatin, etoposide, IEV Ifosfamide, epirubicin, etoposide, miniBEAM carmustine, etoposide, cytarabine, melphalan, Mtx methotrexate, na not available, PR partial response, VAD vincristine, doxorubicin, high-dose dexamethasone, VIM ifosfamide, mitoxantrone, etoposide

ISSN: 1752-1947